PROLONGED PARALYSIS AFTER NEUROMUSCULAR BLOCKADE

被引:14
作者
GOOCH, JL
机构
[1] Primary Children's Medical Center, University of Utah Health Sciences Center, Salt Lake City, UT
来源
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY | 1995年 / 33卷 / 05期
关键词
NEUROMUSCULAR BLOCKADE; NONDEPOLARIZING NEUROMUSCULAR BLOCKING DRUG; PARALYSIS; CORTICOSTEROIDS;
D O I
10.3109/15563659509013750
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Non-depolarizing neuromuscular blocking agents have been used with increasing frequency in critically ill patients. Recently, numerous reports have described patients with prolonged muscle weakness after use of these agents for more than two days. Brief weakness lasting several hours to several days is likely the result of prolonged neuromuscular blockade, while more prolonged weakness lasting several weeks to months is likely caused by a myopathy. Specific features of this myopathic disorder are reviewed. Clinically, patients have flaccid paralysis with intact sensation and cognition. Electrodiagnostic findings include decreased M-wave amplitudes, mild positive waves and fibrillations and small, polyphasic motor unit potentials. Muscle biopsy findings include atrophy of type I and type II fibers, myofiber necrosis and selective loss of thick myofilaments. This myopathic disorder is felt to be related to the prolonged use of non-depolarizing neuromuscular blocking agents either alone or in combination with other medications or disorders. Many authors feel that the disorder is caused specifically by a combination of prolonged neuromuscular blockade and corticosteroids. Selective loss of thick myofilaments on muscle biopsy has been produced experimentally in rats by combining denervation with high doses of corticosteroids. As this disorder likely lends to additional respiratory compromise, difficulty weaning from the ventilator, and prolonged hospitalization, prevention is warranted. Methods of prevention include minimizing the dosage of nondepolarizing neuromuscular blocking agents and of other drugs with an effect on the neuromuscular junction, twitch monitoring with a peripheral nerve stimulator and allowing patients to come to an unparalyzed state for brief periods.
引用
收藏
页码:419 / 426
页数:8
相关论文
共 50 条
[31]   Intraoperative Monitoring of Neuromuscular Blockade [J].
Motamed, Cyrus .
LIFE-BASEL, 2023, 13 (05)
[32]   Incidence and Risk Factors for Postoperative Residual Neuromuscular Blockade [J].
Roy Soto .
Current Anesthesiology Reports, 2020, 10 :81-84
[33]   Monitoring Depth of Neuromuscular Blockade [J].
Srdjan Jelacic ;
Andrew Bowdle ;
Stephan R. Thilen .
Current Anesthesiology Reports, 2023, 13 (4) :229-238
[34]   Neuromuscular Blockade in Paediatric Patients [J].
Keil, Oliver ;
Rigterink, Vanessa .
ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2024, 59 (09) :518-527
[35]   Neuromuscular Blockade in Geriatric Patients [J].
Rudolf, Daniel .
ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2024, 59 (09) :528-536
[36]   NEUROMUSCULAR BLOCKADE IN A PATIENT WITH DERMATOMYOSITIS [J].
ROCKELEIN, S ;
GEBERT, M ;
BAAR, H ;
ENDSBERGER, G .
ANAESTHESIST, 1995, 44 (06) :442-444
[37]   Qualitative Neuromuscular Monitoring: Patterns of Stimulation, Site of Monitoring, and Accuracy in Detecting Residual Neuromuscular Blockade [J].
Moumen Asbahi ;
Roy Soto .
Current Anesthesiology Reports, 2018, 8 (2) :130-133
[38]   Phase II blockade after a subclinical dose of succinylcholine: importance of neuromuscular monitoring [J].
Fabregat-Lopez, J. ;
Ortiz-Gomez, J. R. ;
Moret-Garcia, A. .
REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 2010, 57 (04) :239-242
[39]   Neuromuscular transmission and its pharmacological blockade .1. Neuromuscular transmission and general aspects of its blockade [J].
Booij, LHDJ .
PHARMACY WORLD & SCIENCE, 1997, 19 (01) :1-12
[40]   Sugammadex to Reverse Neuromuscular Blockade Prior to Withdrawal of Life Support [J].
Lemus, Rafael ;
Guider, Will ;
Gee, Samantha W. ;
Humphrey, Lisa ;
Tobias, Joseph D. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2021, 62 (02) :438-442